We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$465M
Cap. Flow
-$336M
Cap. Flow %
-9.38%
Top 10 Hldgs %
52.59%
Holding
77
New
11
Increased
13
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$61.5M
2
LBRX
LB Pharmaceuticals
LBRX
+$53.2M
3
EXAS
Exact Sciences
EXAS
+$50M
4
AKRO
Akero Therapeutics
AKRO
+$46.4M
5
PCVX icon
Vaxcyte
PCVX
+$28.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$176M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$87M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$52.9M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$49.1M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
1
Guardant Health
GH
$18.9B
$260M 7.24%
4,154,086
-95,914
-2% -$5.22M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.03B
$249M 6.95%
3,808,144
-1,083,400
-22% -$52.9M
CYTK icon
3
Cytokinetics
CYTK
$10.7B
$236M 6.6%
4,300,000
+650,000
+18% +$26.8M
AKRO
4
DELISTED
Akero Therapeutics
AKRO
$190M 5.3%
4,000,978
+958,380
+31% +$46.4M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$181M 5.05%
8,000,382
+1,000,382
+14% +$23.3M
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.53B
$178M 4.98%
3,000,000
+1,250,000
+71% +$61.5M
IMVT icon
7
Immunovant
IMVT
$7.8B
$157M 4.38%
9,728,845
+228,845
+2% +$3.7M
DVAX
8
DELISTED
Dynavax Technologies
DVAX
$156M 4.36%
15,726,349
-2,065,137
-12% -$21.5M
OCUL icon
9
Ocular Therapeutix
OCUL
$1.83B
$139M 3.89%
11,932,137
-2,362,283
-17% -$28.2M
ETNB
10
DELISTED
89bio
ETNB
$138M 3.84%
9,356,171
-143,829
-2% -$1.47M
GPCR icon
11
Structure Therapeutics
GPCR
$3.38B
$118M 3.29%
4,215,811
-918,106
-18% -$18.3M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.14B
$116M 3.24%
5,380,449
– –
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.62B
$114M 3.18%
1,715,691
-1,530,208
-47% -$87M
AXSM icon
14
Axsome Therapeutics
AXSM
$11.8B
$109M 3.05%
900,000
+98,629
+12% +$11.1M
PCVX icon
15
Vaxcyte
PCVX
$7.62B
$108M 3.02%
3,000,000
+850,000
+40% +$28.2M
MAZE
16
Maze Therapeutics
MAZE
$1.51B
$102M 2.86%
3,948,910
– –
IMCR icon
17
Immunocore
IMCR
$1.68B
$65.4M 1.83%
1,800,000
– –
BBIO icon
18
BridgeBio Pharma
BBIO
$16.5B
$62.3M 1.74%
1,200,000
+300,000
+33% +$14.6M
GERN icon
19
Geron
GERN
$905M
$56.3M 1.57%
41,096,522
-1,903,478
-4% -$2.53M
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
$56.3M 1.57%
7,495,000
– –
NRIX icon
21
Nurix Therapeutics
NRIX
$2.43B
$56M 1.56%
6,057,024
-7,886
-0.1% -$81.9K
MBX
22
MBX Biosciences
MBX
$2.99B
$55.1M 1.54%
3,150,000
+961,408
+44% +$12.9M
EXAS
23
DELISTED
Exact Sciences
EXAS
$54.7M 1.53%
+1,000,000
New +$50M
LBRX
24
LB Pharmaceuticals
LBRX
$1.07B
$52.9M 1.48%
+3,352,804
New +$53.2M
CLDX icon
25
Celldex Therapeutics
CLDX
$2.84B
$51.7M 1.44%
2,000,000
– –
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Deep Track Capital held 77 positions worth $3.58B, up 15% from $3.12B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital withdrew a net $336M in Q3 2025, closing 21 positions and reducing 21 holdings. Its most notable exit was Insmed, an estimated $176M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in LB Pharmaceuticals worth $52.9M.

  • Deep Track Capital's largest Q3 2025 buy was LB Pharmaceuticals: 3,352,804 shares worth $52.9M.
  • Deep Track Capital added most to Tarsus Pharmaceuticals in Q3 2025, an estimated $61.5M increase.
  • Deep Track Capital's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $87M.
  • Deep Track Capital fully exited Insmed in Q3 2025, selling an estimated $176M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.58B portfolio in Q3 2025.
  • Deep Track Capital opened 11 new positions and closed 21 in Q3 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.58B.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.